The abstract is read at the publisher; the summary is JClub's.
Capivasertib plus abiraterone improves overall survival in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer, with OS median 57.4 vs 46.5 months (HR 0.82).
- Why it matters: PTEN-deficient de novo mHSPC has poor prognosis and limited benefit from standard care, leaving a high unmet need for more effective targeted options.
- What they did: In CAPItello-281, patients with PTEN-deficient tumors (≥90% viable malignant cells without specific cytoplasmic staining) were randomized 1:1 to capivasertib plus abiraterone or placebo plus abiraterone; ad hoc descriptive analyses were done at 42% OS maturity.
- The result: At the 9 March 2026 data cut-off (median follow-up 39 months), OS favored capivasertib plus abiraterone (HR 0.82, 95% CI 0.68–0.99, P=0.044), with updated rPFS also consistent (HR 0.83, 95% CI 0.70–0.99, nominal P=0.033).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.